Michael Kalos

Best Publications

• Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

  David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

  4413
  Citations

• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

  4108
  Citations

• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

  3117
  Citations

• Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

  Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

  1662
  Citations

• Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

  Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  1317
  Citations

• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

  976
  Citations

• NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

  Aaron P Rapoport;Edward A Stadtmauer;Gwendolyn K Binder-Scholl;Olga Goloubeva

  961
  Citations

• Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

  Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

  863
  Citations

• Monoclonal TCR-redirected tumor cell killing

  Nathaniel Liddy;Giovanna Bossi;Katherine J. Adams;Anna Lissina

  795
  Citations

• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

  766
  Citations

• Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

  Brian J. Cameron;Andrew B. Gerry;Joseph Dukes;Jane V. Harper

  755
  Citations

• Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

  David T. Teachey;David T. Teachey;Susan R. Rheingold;Susan R. Rheingold;Shannon L. Maude;Shannon L. Maude;Gerhard Zugmaier

  680
  Citations

• T cells expressing chimeric antigen receptors can cause anaphylaxis in humans

  Marcela V. Maus;Andrew R. Haas;Gregory L. Beatty;Steven M. Albelda

  668
  Citations

• Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

  Michael C. Jensen;Leslie Popplewell;Laurence J. Cooper;David DiGiusto

  637
  Citations

• Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

  Marco Ruella;David M. Barrett;Saad S. Kenderian;Olga Shestova

  598
  Citations

• Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

  Michael Kalos;Carl H. June

  587
  Citations

• Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

  Saar Gill;Sarah K. Tasian;Marco Ruella;Olga Shestova

  541
  Citations

• RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma

  David L. DiGiusto;Amrita Krishnan;Lijing Li;Haitang Li

  493
  Citations

• Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

  Matthew J. Frigault;Jihyun Lee;Maria Ciocca Basil;Carmine Carpenito

  355
  Citations

• Adoptive Immunotherapy for Cancer or Viruses

  Marcela V. Maus;Joseph A. Fraietta;Bruce L. Levine;Michael Kalos

  332
  Citations